These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37260182)

  • 21. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
    Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy.
    Iannicelli E; Di Pietropaolo M; Pilozzi E; Osti MF; Valentino M; Masoni L; Ferri M
    Abdom Radiol (NY); 2016 Oct; 41(10):1906-17. PubMed ID: 27323759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
    Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
    Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.
    Lin SC; Chen PC; Lee CT; Tsai HM; Lin PC; Chen HH; Wu YH; Lin BW; Su WP; Lee JC
    World J Gastroenterol; 2013 Mar; 19(11):1797-804. PubMed ID: 23555168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.
    Boissière-Michot F; Lopez-Crapez E; Frugier H; Berthe ML; Ho-Pun-Cheung A; Assenat E; Maudelonde T; Lamy PJ; Bibeau F
    Mod Pathol; 2012 May; 25(5):731-9. PubMed ID: 22282307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results.
    Jang KM; Kim SH; Choi D; Lee SJ; Park MJ; Min K
    Br J Radiol; 2012 Sep; 85(1017):e566-72. PubMed ID: 22422387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
    Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up.
    Mancini R; Pattaro G; Diodoro MG; Sperduti I; Garufi C; Stigliano V; Perri P; Grazi GL; Cosimelli M
    Clin Colorectal Cancer; 2018 Mar; 17(1):e13-e19. PubMed ID: 28865674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.
    Sorenson E; Lambreton F; Yu JQ; Li T; Denlinger CS; Meyer JE; Sigurdson ER; Farma JM
    J Surg Res; 2019 Nov; 243():242-248. PubMed ID: 31229791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lee IH; Kang K; Kang BW; Lee SJ; Bae WK; Hwang JE; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    Med Oncol; 2018 Sep; 35(11):145. PubMed ID: 30206710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.
    Shaish H; Aukerman A; Vanguri R; Spinelli A; Armenta P; Jambawalikar S; Makkar J; Bentley-Hibbert S; Del Portillo A; Kiran R; Monti L; Bonifacio C; Kirienko M; Gardner KL; Schwartz L; Keller D
    Eur Radiol; 2020 Nov; 30(11):6263-6273. PubMed ID: 32500192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.